Vivos Therapeutics, Inc.

Historical 13F Holders

Symbol
VVOS
CUSIP
92859E207
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 92859E207 since 12/18/2024, newest first.

Filer % of Class Filed
Streeterville Capital LLC 13G/A Amendment 1
0.6% 9/3/2026
Event 9/3/2026
Armistice Capital, LLC 13G/A Amendment 1
4.99% 8/14/2026
Event 6/30/2026
Streeterville Capital LLC 13G
9.3% 8/11/2026
Event 8/11/2026
V-Co Investors 4 LLC 13D
19.9% 7/15/2026
Event 6/30/2026
Armistice Capital, LLC 13G
8.3% 5/15/2026
Event 3/31/2026
V-Co Investors 3 LLC 13D
19.9% 4/2/2026
Event 3/31/2026
Dawei Luo 13G 8.5% 7/14/2025
Event 7/8/2025
V-CO Investors LLC 13D
19.9% 6/16/2025
Event 6/9/2025
Intracoastal Capital LLC 13G
4.99% 12/30/2024
Event 12/22/2024
V-CO Investors LLC 13G
9.9% 12/20/2024
Event 12/17/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 2 70.8 k $10.5 k
2026 Q2 22 531 k $243 k
2026 Q1 24 1.82 M $2.15 M
2025 Q4 19 658 k $1.34 M
2025 Q3 23 687 k $2.13 M
2025 Q2 21 402 k $1.27 M
2025 Q1 22 351 k $1.00 M
2024 Q4 21 467 k $2.00 M
2024 Q3 24 245 k $631 k
2024 Q2 22 187 k $434 k
2024 Q1 19 137 k $647 k
2023 Q4 19 253 k $3.12 M